Correction to: Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations
Clinical Scorecard: Erratum: Evaluating Brainstem Impacts and Outcome Correlations of Quantitative Susceptibility Mapping at 7 Tesla in COVID-19
At a Glance
| Category | Detail |
| Condition | Neurological impacts of COVID-19 on the brainstem |
| Key Mechanisms | Quantitative susceptibility mapping (QSM) at 7 Tesla MRI to assess brainstem changes |
| Target Population | Patients with COVID-19 |
| Care Setting | Research and clinical neuroimaging settings |
Key Highlights
- QSM at 7T used to evaluate brainstem effects in COVID-19 patients
- Outcome associations of brainstem changes identified via advanced imaging
- Corrections issued regarding acknowledgements and funding disclosures
Guideline-Based Recommendations
Diagnosis
- Utilize high-field 7 Tesla MRI with quantitative susceptibility mapping for detailed brainstem assessment in COVID-19 neurological studies
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
COVID-19 patients undergoing neurological evaluation
No direct treatment recommendations; imaging findings may inform prognosis and research
Clinical Best Practices
- Ensure accurate and comprehensive acknowledgements and funding disclosures in research publications
- Adopt advanced neuroimaging techniques like QSM at 7T for detailed brainstem evaluation in COVID-19
- Collaborate across research centers and maintain rigorous ethical and procedural standards during pandemic conditions
References